These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 21995543)

  • 1. Co-administration of an α(1) -blocker improves the efficacy and safety of antimuscarinic agents in rats with detrusor overactivity.
    Nagase K; Ito H; Aoki Y; Tanase K; Akino H; Yokoyama O
    Int J Urol; 2011 Dec; 18(12):836-43. PubMed ID: 21995543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency.
    Kaplan SA; McCammon K; Fincher R; Fakhoury A; He W
    J Urol; 2009 Dec; 182(6):2825-30. PubMed ID: 19837435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms--ASSIST, randomized controlled study.
    Yamaguchi O; Kakizaki H; Homma Y; Takeda M; Nishizawa O; Gotoh M; Yokoyama O; Seki N; Yoshida M;
    Urology; 2011 Jul; 78(1):126-33. PubMed ID: 21601248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of solifenacin succinate (YM905) on detrusor overactivity in conscious cerebral infarcted rats.
    Suzuki M; Ohtake A; Yoshino T; Yuyama H; Hayashi A; Ukai M; Okutsu H; Noguchi Y; Sato S; Sasamata M
    Eur J Pharmacol; 2005 Apr; 512(1):61-6. PubMed ID: 15814091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimuscarinic drug inhibits detrusor overactivity induced by topical application of prostaglandin E2 to the urethra with a decrease in urethral pressure.
    Yokoyama O; Miwa Y; Oyama N; Aoki Y; Ito H; Akino H
    J Urol; 2007 Nov; 178(5):2208-12. PubMed ID: 17870108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial.
    Kaplan SA; He W; Koltun WD; Cummings J; Schneider T; Fakhoury A
    Eur Urol; 2013 Jan; 63(1):158-65. PubMed ID: 22831853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of solifenacin add-on therapy to α-blocker treated men with residual urgency and frequency.
    Kaplan SA; McCammon K; Fincher R; Fakhoury A; He W
    J Urol; 2013 Jan; 189(1 Suppl):S129-34. PubMed ID: 23234618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of antimuscarinics on voiding function after cerebral infarction in a rat model of overactive bladder.
    Yusup A; Akino H; Miwa Y; Oyama N; Aoki Y; Ito H; Tanase K; Matsuta Y; Nakai M; Yokoyama O
    Eur J Pharmacol; 2007 Dec; 577(1-3):143-9. PubMed ID: 17904547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland.
    Ikeda K; Kobayashi S; Suzuki M; Miyata K; Takeuchi M; Yamada T; Honda K
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Aug; 366(2):97-103. PubMed ID: 12122494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urodynamic parameters after solifenacin treatment in men with overactive bladder symptoms and detrusor underactivity.
    Ronchi P; Gravina GL; Galatioto GP; Costa AM; Martella O; Vicentini C
    Neurourol Urodyn; 2009; 28(1):52-7. PubMed ID: 18671288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solifenacin pharmacology.
    Morales-Olivas FJ; Estañ L
    Arch Esp Urol; 2010; 63(1):43-52. PubMed ID: 20157218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of solifenacin in patients with neurogenic detrusor overactivity as a result of spinal cord lesion.
    Krebs J; Pannek J
    Spinal Cord; 2013 Apr; 51(4):306-9. PubMed ID: 23247012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents.
    Ohtake A; Saitoh C; Yuyama H; Ukai M; Okutsu H; Noguchi Y; Hatanaka T; Suzuki M; Sato S; Sasamata M; Miyata K
    Biol Pharm Bull; 2007 Jan; 30(1):54-8. PubMed ID: 17202659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of solifenacin to treat overactive bladder symptoms in patients with idiopathic normal pressure hydrocephalus: an open-label, multicenter, prospective study.
    Chung JH; Lee JY; Kang DH; Ha US; Lee SH; Ham WS; Cho KS; Han JH; Park J; Yoo TK; Lee SW
    Neurourol Urodyn; 2012 Sep; 31(7):1175-80. PubMed ID: 22674356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: ameliorative effect of solifenacin succinate (Vesicare), a bladder-selective antimuscarinic agent, on overactive bladder symptoms, especially urgency episodes.
    Ohtake A; Sato S; Sasamata M; Miyata K
    J Pharmacol Sci; 2010; 112(2):135-41. PubMed ID: 20134114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solifenacin succinate for the treatment of symptoms of overactive bladder.
    Maniscalco M; Singh-Franco D; Wolowich WR; Torres-Colón R
    Clin Ther; 2006 Sep; 28(9):1247-72. PubMed ID: 17062299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological effects of solifenacin on human isolated urinary bladder.
    Masunaga K; Yoshida M; Inadome A; Murakami S; Sugiyama Y; Satoji Y; Maeda Y; Ueda S
    Pharmacology; 2008; 82(1):43-52. PubMed ID: 18434763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Solifenacin.
    Kreder KJ
    Urol Clin North Am; 2006 Nov; 33(4):483-90, ix. PubMed ID: 17011384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological and genetic analysis of mechanisms underlying detrusor overactivity in rats.
    Yokoyama O
    Neurourol Urodyn; 2010; 29(1):107-11. PubMed ID: 20025014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial.
    Cardozo L; Hessdörfer E; Milani R; Arañó P; Dewilde L; Slack M; Drogendijk T; Wright M; Bolodeoku J;
    BJU Int; 2008 Nov; 102(9):1120-7. PubMed ID: 18990175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.